Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | CAR-T cell therapy: an exciting field in ALL

Nitin Jain • 11 Dec 2017
ASH 2017
Acute Lymphoblastic Leukemia Leukemia CAR-T

One of the current exciting fields in ALL is CAR-T cell therapies. Nitin Jain, MD of the University of Texas MD Anderson Cancer Center, Houston, TX , gives an overview of some of his CAR-T cell therapy highlights from ASH 2017.

More from Nitin Jain

1:13
5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax
Nitin Jain • 10 Dec 2023
1:06
An ongoing Phase I trial evaluating AS-1763, a novel non-covalent BTKi, in B-cell lymphomas
Nitin Jain • 10 Dec 2023
1:43
Long-term outcomes of the iFCG regimen for firstline treatment of patients with IGHV-mutated CLL
Nitin Jain • 10 Dec 2023
1:54
Nivolumab + ibrutinib for patients with Richter’s transformation
Nitin Jain • 7 Sep 2023

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals